Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq Warns OpGen About Overdue 2023 Annual Report

NEW YORK – Molecular diagnostics firm OpGen said Tuesday that it has received a notice from the Nasdaq that the company has failed to comply with a listing requirement to file in a timely manner its annual report for 2023 with the US Securities and Exchange Commission.

Rockville, Maryland-based OpGen said that it had notified the SEC that it was unable to file its annual Form 10-K by April 1 without unreasonable effort or expense. The company said that it has been finalizing a Form 10-K report for 2023 and plans to file it "as soon as practicable" to regain compliance with the Nasdaq requirement.

If the Nasdaq Hearings Panel allows more time to regain compliance, the company expects it will be required to file the form no later than June 3 to avoid a delisting determination.

OpGen was also warned by the exchange in June 2023 that the company's common stock had fallen below the minimum bid price of $1.00 per share for 30 consecutive business days. Company officials announced in February that the Nasdaq Hearings Panel had granted their request for continued listing and gave the firm until June 3 to regain compliance with the exchange's minimum bid price requirement.

OpGen's Curetis and Ares Genetics subsidiaries filed for bankruptcy in November. OpGen said that it had been unable to sell those businesses or their assets to secure additional capital.

OpGen's shares opened on Wednesday morning down about 2 percent trading at $.60 per share.